Objective: The objective of this study is to evaluate the costs and benefits of Isiris (Coloplast, Denmark), a mobile, single-use, flexible cystoscope with a built-in stent grasper. Methods: A prospectively collected database was reviewed to define procedural outcomes for Isiris ureteric stent removal. Variables assessed included stent duration and location of removal. A cost assessment was performed evaluating the impact on costs, funding and facility use. Results: Seventy-five procedures were performed using Isiris between April and September 2017. There were no complications. Two procedures failed because of encrustation and poor visibility secondary to haematuria. The mean (SD), median (interquartile range) and range of delay were 2.1 (0–5.3), 0 (0–2) and 0–40 days, respectively. Only one patient was delayed more than two weeks; this occurred because he was placed on a theatre waiting list, which resulted in the 40-day delay. Overall, the cost benefit for our department with the introduction of the Isiris system has been a surplus of $104,434, with an extra 65 elective spaces free for diagnostic flexible cystoscopy cases. Conclusion: Isiris flexible stent removal offers our patients a rapid stent-removal service with low rates of removal delay. Savings have been made in scope repair costs, sterilisation and scope maintenance, as well as optimisation of theatre and procedure room space. Level of evidence: 1c
12 September 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Objectives: Haematuria is a common urological complaint that carries a significant burden to our healthcare system. Due to the complex investigation algorithm for haematuria, incomplete referrals result in multiple appointments. We established the “streamlined haematuria pathway” (SHP) phone clinic, and this study evaluated the effect of SHP on waiting times, patient care and time to treatment. Methods: A retrospective analysis of all patients who were reviewed via our SHP was performed, including time to see and outcomes. The effects of implementing the SHP on our health system were assessed by analysing our referral waitlists and costings department. Results: On starting the SHP phone clinic there were 1031 referrals waiting longer than clinical recommended time frames, and of these 92 were identified as a patient with haematuria. The majority of patients were male sex (55%), had microscopic haematuria (63%), and the median age was 69 years. There were 12 (30%) patients who were waiting 100 days or more before the phone clinic was introduced. A total of 87% patients were discharged post-normal outcomes, 5% patients had stones and 8% patients were diagnosed with bladder malignancy. Conclusions: The SHP phone clinic is an effort to decrease morbidity and mortality by earlier diagnosis of urological malignancy. Level of evidence: 3-b